Most studies have examined the use of one of two classes of insulin‐sensitizing drugs on NASH: thiazolidinediones (pioglitazone and rosiglitazone) or biguanides (metformin), for improving insulin resistance as a possible treatment for NASH (Van Wagner & Rinella, 2011; Xu et al., 2016). Here, INS is linked to metabolic dysfunction-associated steatohepatitis.